Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have drastically changed treatments of advanced melanoma. However, ICI-related enterocolitis is often the most common adverse event, and represents the main reason for ICI discontinuation and mortalities. Here, we report the case...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneoka, Ayaka, Okada, Etsuko, Sugino, Hitomi, Saito-Sasaki, Natsuko, Omoto, Daisuke, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870896/
https://www.ncbi.nlm.nih.gov/pubmed/35204571
http://dx.doi.org/10.3390/diagnostics12020480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870896/
https://www.ncbi.nlm.nih.gov/pubmed/35204571
http://dx.doi.org/10.3390/diagnostics12020480

Ejemplares similares